| Code | CSB-RA011587MB6HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to ustekinumab-stba, designed to target IL12B, a shared subunit (p40) of both interleukin-12 (IL-12) and interleukin-23 (IL-23). IL12B plays a critical role in inflammatory and immune responses by linking innate and adaptive immunity. IL-12 promotes Th1 cell differentiation and interferon-gamma production, while IL-23 supports Th17 cell maintenance and pro-inflammatory cytokine secretion. Dysregulation of IL12B-mediated signaling is implicated in various autoimmune and inflammatory conditions, including psoriasis, psoriatic arthritis, Crohn's disease, and inflammatory bowel disease.
Ustekinumab-stba is a therapeutic antibody approved for treating moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn's disease by neutralizing the p40 subunit shared by IL-12 and IL-23. This biosimilar provides researchers with a valuable tool for investigating IL12B-dependent pathways, studying cytokine-mediated immune regulation, and exploring therapeutic mechanisms in inflammatory disease models. It supports immunological research and preclinical studies examining the role of IL-12/IL-23 axis in autoimmunity and inflammation.
There are currently no reviews for this product.